Revenue rose to $13.2M from $7.6M a year earlier while net loss widened to $61.9M, with the company also pointing to progress in its obesity pipeline.
Recap by typeshit. Post by alldaystocks on X.
The $49 virtual weight management visits now cover insurance checks and Medicare GLP-1 Bridge support, with pharmacists contacting everyone who starts a fill.
A press release announces Woodward's new book, which she says debunks common peptide myths aimed at women. No other details were given.
A local feature on clinics in Sarasota using peptides for recovery, hormones and wellness. The claims come from the practitioners and are not backed by cited evidence.
Endpoints News
The Copenhagen drugmaker has a slate of weight loss candidates but says its future depends on building a much wider pipeline.
An explainer on the FDA approval of Lilly's Zepbound and what it changes for patients and providers. Older news with no new details given.
Zacks expects $10.1 billion from Mounjaro and $5.1 billion from Zepbound, and notes Lilly plans to seek retatrutide approval in early 2027.
Loading…